Rosanna Sutherby, Pharm.D.

Advances in MS disease management have included the emergence of monoclonal antibodies as effective disease-modifying therapies (DMTs) for MS. FDA-approved treatments include Tysabri (natalizumab), Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), and Kesimpta (ofatumumab).

In a retrospective study, researchers from Humana in Louisville, KY, compared clinical outcomes, time on treatment, healthcare resources utilization, and relative costs in patients with MS that were newly initiated on one of the following oral DMTs: dimethyl fumarate, fingolimod, or teriflunomide.

Studies have shown that the use of oral corticosteroids in patients with UC is associated with higher rates of adverse effects and use of healthcare resources compared with biologics or immunosuppressants. However, there is little research focusing on the economic and clinical burden of chronic corticosteroid use among people living with UC.

Historically, health disparities have disproportionately affected underrepresented people with MS, particularly Black and Latinx females.

The success of mRNA vaccines against COVID-19 has led to a surge of mRNA vaccines being developed for other diseases.

Study authors hypothesized that factors such as depression, IBD medications, and stomach or rectal surgery may play a role in the increased risk of erectile dysfunction in patients with IBD.

Research scientist Dr. Cristina A. F. Román, based at the Kessler Foundation’s Rocco Ortenzio Neuroimaging Center, secured a $704,054 grant for a five-year mixed-method study exploring the impact of healthcare barriers on cardiovascular risk factors and accelerated brain aging in Latinos with multiple sclerosis (MS), an under-researched community facing more severe disease outcomes;

A recent study found all women with a first-time perinatal depression diagnosis or who had been prescribed an antidepressant from the estimated date of conception to one year postpartum.

Ocrevus (ocrelizumab), marketed by Genentech, is a CD20-directed monoclonal antibody FDA-approved in 2017 to treat relapsing forms of multiple sclerosis (MS) as well as primary progressive MS (PPMS). It's currently the only disease-modifying treatment approved for treating PPMS.

The CAR T-cell therapy targets the CD19 protein ubiquitous on the surface of B cells, which are known to mediate various types of autoimmune diseases, including MS.

Janssen Biotech's Remicade (infliximab), an FDA-approved tumor necrosis factor inhibitor since 1998 for Crohn's disease, has gained additional approvals for managing ulcerative colitis and rheumatoid arthritis.

The American Gastroenterological Association recommendations do not take a stand for or against using probiotics for those with intermittent pouchitis.

Lipoprotein(a) is a cardiovascular disease risk factor that does not change with diet and exercise. There are no FDA-approved treatments, but two candidates are in phase 3 trials.

A subset of natural killer cells may be a potential target for the development of agents protective against MS.

Inflammatory bowel disease (IBD) clinical trials often involve participants getting numerous endoscopies. Cutting back on the number of endoscopies and using noninvasive tests instead was one of the ideas discussed for how to improve clinical trial design.

Funding will go to six recipients of the Challenges in Progressive MS Awards and nine to the Innovation in Well-Being Awards.

In an effort to reduce financial and other quality of life burdens for individuals living with ulcerative colitis, Hongliang Chen and his colleagues from the Department of Gastroenterology and Hepatology at four medical centers in northeast China sought to develop a routine blood-based tool for assessing the extent and severity of ulcerative colitis.

In a study recently published in the journal Fertility and Sterility, researchers from the University of Queensland in Brisbane, Australia, evaluated the fertility treatment pathways used by participants with and without PCOS to determine which pathways resulted in more live births.

Ayble Health says it provides personalized nutrition and psychology services, Higher-risk patients will have expedited scheduling with Mayo Clinic multidisciplinary experts.

Study shows that MRI imaging can identify cortical lesions and the central vein sign that are informative in diagnosing multiple sclerosis.

The most common barriers were logistical and access, according to results of a cross-sectional study published in JAMA Network Open.

A potential mechanism by which air pollutants may affect reproductive health is by endocrine disruption. Air pollutants are made up of mixtures of particulate matter that may include endocrine disruptors, such as polycyclic aromatic hydrocarbons (PAHs) and heavy metals.

The updated guidelines include 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments.

Vidofludimus calcium is a potential first-in-class nuclear receptor related 1 (Nurr1) activator and a selective dihydroorotate dehydrogenase (DHODH) inhibitor.

Expensive gene therapy has grabbed the headlines, but three promising drugs that work in the coagulation pathway are in late-stage development.

For patients with ulcerative colitis, levels of C-reactive protein, leukocytes, neutrophils, eosinophils, and platelets were significantly higher compared with controls three years before diagnosis.

Chronic systemic inflammation is believed to play a significant role in the association between inflammatory bowel disease and increased risk of arrhythmias.

It is believed that reasons for these racial disparities may include socioeconomic factors, but the true causes are not fully understood. Some researchers believe that immunologic differences may also play a role.

A ketogenic diet, which is low carbohydrates and rich in fat, is linked to successful in vitro fertilization in people with polycystic ovary syndrome.

Delgocitinib is first-in-class pan-Janus kinase inhibitor